<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096187</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000390347</org_study_id>
    <secondary_id>GOG-0217</secondary_id>
    <secondary_id>GOG-UC0205</secondary_id>
    <secondary_id>LILLY-H3E-US-JMGR</secondary_id>
    <nct_id>NCT00096187</nct_id>
  </id_info>
  <brief_title>Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy</brief_title>
  <official_title>A Phase II Trial of Pemetrexed (ALIMTA®, LY231514, IND #40061) as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to
      stop tumor cells from dividing so they stop growing or die.

      PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating
      patients with recurrent or persistent low-risk gestational trophoblastic tumor after a molar
      pregnancy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the activity of pemetrexed disodium as salvage therapy in patients with
           persistent or recurrent low-risk post-molar gestational trophoblastic tumor that failed
           prior dactinomycin or methotrexate.

        -  Determine the toxicity of this drug in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21
      days in the absence of unacceptable toxicity or disease progression or until tumor marker
      levels (human chorionic gonadotropin [hCG]) become normal. Patients receive 2 additional
      courses beyond the attainment of a normal hCG.

      Beginning 7 days before and continuing until 3 weeks after the last dose of pemetrexed
      disodium, patients also receive oral folic acid daily and cyanocobalamin (vitamin B_12)
      intramuscularly every 9 weeks.

      Patients are followed every 2 weeks for 2 months and then monthly for 10 months.

      PROJECTED ACCRUAL: Approximately 17-55 patients will be accrued for this study within 20-50
      months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 2005</start_date>
  <primary_completion_date type="Actual">July 23, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Activity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Gestational Trophoblastic Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of low-risk post-molar gestational trophoblastic tumor, defined as 1 of the
             following:

               -  Increasing human chorionic gonadotropin (hCG) levels on ≥ 3 consecutive
                  measurements taken over ≥ a 2-week period

               -  Less than 10% decrease of hCG levels on 4 measurements taken over ≥ a 3-week
                  period

          -  Persistent or recurrent disease

          -  Histologically confirmed complete or partial mole on initial evacuation

               -  Prior pregnancy ≤ 12 months ago

          -  No histologically confirmed choriocarcinoma or placental site trophoblastic tumor on
             initial evacuation

          -  Failed only 1 prior dactinomycin or methotrexate therapy (with or without leucovorin
             calcium)

          -  WHO score 2-6

          -  No evidence of metastatic disease, except to the lung or vagina, on physical exam,
             chemistry, chest X-ray, and ultrasound

               -  No liver, spleen, brain, kidney, or gastrointestinal tract metastases

               -  No more than 8 metastatic lesions

        PATIENT CHARACTERISTICS:

        Age

          -  Any age

        Performance status

          -  GOG 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Granulocyte count ≥ 1,500/mm^3

        Hepatic

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  SGOT ≤ 3 times ULN

          -  Alkaline phosphatase ≤ 3 times ULN

        Renal

          -  Creatinine ≤ 1.5 mg/dL

          -  Creatinine clearance ≥ 45 mL/min

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 3 months after study
             participation

          -  No significant infection

          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent prophylactic filgrastim (G-CSF) unless for recurrent neutropenic
             complications

          -  No concurrent prophylactic thrombopoietic agents unless for recurrent grade 4
             thrombocytopenia

        Chemotherapy

          -  See Disease Characteristics

          -  At least 7 days since prior dactinomycin or methotrexate (with or without leucovorin
             calcium) and recovered

          -  No prior pemetrexed disodium

          -  No other prior chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  At least 14 days since prior radiotherapy and recovered

          -  No prior radiotherapy to ≥ 25% of the bone marrow

        Surgery

          -  Recovered from prior surgery

        Other

          -  No nonsteroidal anti-inflammatory drugs or salicylates for 2 days (or 5 days for drugs
             with a long half-life) before, during, and for 2 days after pemetrexed disodium
             administration

               -  Concurrent low-dose aspirin (≤ 325 mg/day) allowed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David S. Miller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allan Covens, MD</last_name>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Saint Joseph Medical Center - Burbank</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hinsdale Hematology Oncology Associates</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Regional Health Center</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hulston Cancer Center at Cox Medical Center South</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at Cooper - Voorhees</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blumenthal Cancer Center at Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232-2861</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilson Medical Center</name>
      <address>
        <city>Wilson</city>
        <state>North Carolina</state>
        <zip>27893-3428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles M. Barrett Cancer Center at University Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital Cancer Care</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214-3998</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillcrest Cancer Center at Hillcrest Hospital</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake/University Ireland Cancer Center</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Cancer Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosenfeld Cancer Center at Abington Memorial Hospital</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19612-6052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Southwest Cancer and Research Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79415-3364</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2004</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <keyword>low risk metastatic gestational trophoblastic tumor</keyword>
  <keyword>recurrent gestational trophoblastic tumor</keyword>
  <keyword>nonmetastatic gestational trophoblastic tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trophoblastic Neoplasms</mesh_term>
    <mesh_term>Gestational Trophoblastic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

